➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,820,938

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,820,938 protect, and when does it expire?

Patent 9,820,938 protects PARSABIV and is included in one NDA.

This patent has forty-one patent family members in thirty-six countries.

Summary for Patent: 9,820,938
Title:Stable liquid formulation of AMG 416 (etelcalcetide)
Abstract: A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.
Inventor(s): Maclean; Derek (Los Altos, CA), Yin; Qun (Palo Alto, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Application Number:14/908,481
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,820,938
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 9,820,938

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kai Pharms Inc PARSABIV etelcalcetide SOLUTION;INTRAVENOUS 208325-001 Feb 7, 2017 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Kai Pharms Inc PARSABIV etelcalcetide SOLUTION;INTRAVENOUS 208325-002 Feb 7, 2017 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Kai Pharms Inc PARSABIV etelcalcetide SOLUTION;INTRAVENOUS 208325-003 Feb 7, 2017 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,820,938

PCT Information
PCT FiledJune 27, 2014PCT Application Number:PCT/US2014/044622
PCT Publication Date:December 31, 2014PCT Publication Number: WO2014/210489

International Family Members for US Patent 9,820,938

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 096773 ⤷  Free Forever Trial
Australia 2014302122 ⤷  Free Forever Trial
Brazil 112015032615 ⤷  Free Forever Trial
Canada 2916222 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.